Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2

• Published in: Frontiers in immunology Vol. 13; p. 845887
• Main Authors: Mooij, Petra, García-Arriaza, Juan, Pérez, Patricia, Lázaro-Frías, Adrian, Verstrepen, Babs E., Böszörményi, Kinga P., Mortier, Daniella, Fagrouch, Zahra, Kiemenyi-Kayere, Gwendoline, Niphuis, Henk, Acar, Roja Fidel, Meijer, Lisette, Stammes, Marieke A., Kondova, Ivanela, Verschoor, Ernst J., GeurtsvanKessel, Corine H., de Bruin, Erwin, Sikkema, Reina S., Luczkowiak, Joanna, Delgado, Rafael, Montenegro, Dolores, Puentes, Eugenia, Rodríguez, Esteban, Bogers, Willy M. J. M., Koopman, Gerrit, Esteban, Mariano
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 16.03.2022
• Subjects: Animals; Antibodies, Viral; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Humans; Immunology; Macaca mulatta; MVA vaccine; Pandemics; rhesus macaques; safety; SARS-CoV-2; SARS-CoV-2 - genetics; spike; Spike Glycoprotein, Coronavirus; Vaccinia virus - genetics; COVID-19; SARS-CoV-2; rhesus macaques; safety; efficacy; immunogenicity; MVA vaccine; spike

Novel safe, immunogenic, and effective vaccines are needed to control the COVID-19 pandemic, caused by SARS-CoV-2. Here, we describe the safety, robust immunogenicity, and potent efficacy elicited in rhesus macaques by a modified vaccinia virus Ankara (MVA) vector expressing a full-length SARS-CoV-2...